The P value in a small trial is generally reflective of the small sample size rather than efficacy. If you combine all the data such as survival, NFL changes and AFS score, you see they all suggest that MPL is slowing disease progression. Add to that the significant improvement gained from the increased dosage enjoyed by cohort 2 and it's hard to prescribe any other reason for the improvements other than that MPL is effective in treating MND/ALS. With consistent data correlation I'd put p value at .001. I may be wrong, it's probably better than that.
- Forums
- ASX - By Stock
- PAA
- The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-954
-
- There are more pages in this discussion • 471 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
|
|||||
Last
18.5¢ |
Change
-0.010(5.13%) |
Mkt cap ! $92.38M |
Open | High | Low | Value | Volume |
19.0¢ | 19.0¢ | 18.5¢ | $70.82K | 381.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 218740 | 18.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
19.0¢ | 89682 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 218740 | 0.185 |
17 | 341021 | 0.180 |
5 | 414700 | 0.175 |
5 | 224303 | 0.170 |
3 | 9700 | 0.165 |
Price($) | Vol. | No. |
---|---|---|
0.190 | 89682 | 4 |
0.195 | 152119 | 7 |
0.200 | 373778 | 11 |
0.205 | 147000 | 2 |
0.210 | 238902 | 5 |
Last trade - 11.24am 05/08/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |